Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1304-1311

  Small, E J ^a   McMillan, A ^a   Meyer, M ^a   Chen, L ^a   Slichenmyer, W J ^a   Lenehan, P F ^a   Eisenberger, M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; NARCOTIC ANALGESIC AGENT; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035281497     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1304     Document Type: Article

References (21)

1. Clinical trials in relapsed prostate cancer: Defining the target
2. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
3. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
4. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
5. Evaluation of prostate specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy
6. Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials
7. Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
8. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
9. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients
10. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
11. Suramin therapy for patients with symptomatic hormone refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
12. Nonparametric estimation from incomplete observations
13. Analysis of survival by tumor response
14. Regression models and life-tables (with discussion)
15. Quality of life and treatment of hormone-resistant metastatic prostate cancer
16. Pain assessment: Global use of the Brief Pain Inventory
17. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer
18. Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 Study
19. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
20. Surrogate endpoints in clinical trials: Definition and operational criteria
21. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!